Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nano CED: Liposomal Irinotecan in Recurrent High Grade Glioma
NCT02022644Phase 1Completed
- Sponsor
- University of California, San Francisco
- Start
- Oct 2014
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of irinotecan in high-grade glioma (HGG) (8 arms), sponsored by University of California, San Francisco. Primary endpoint: Maximum Tolerated Dose. Started Oct 2014; status: completed.
02
Drugs
irinotecan
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT02022644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02022644.